Efficacy and the Safety Study of RD94 in Patients With Endodontic Care

This study has been completed.
Sponsor:
Collaborator:
AscoPharm is conducting the study under the responsibility of SEPTODONT
Information provided by (Responsible Party):
Ascopharm Groupe Novasco
ClinicalTrials.gov Identifier:
NCT01737229
First received: November 6, 2012
Last updated: July 23, 2013
Last verified: July 2013
  Purpose

TRIAL TITLE Open trial, not randomized study evaluating the efficacy and the tolerance of RD94 in patients needing endodontic care, medical device class III.

SPONSOR:

SEPTODONT, 58 rue de Pont de Créteil, 94107 Saint Maur des Fossés cedex Tel : + 33 1-49-76-74-26, Fax. : + 33 1- 49-76-71-91

Reference protocol: 09/001

PRODUCT NAME: Biodentine™ (RD94)

MEDICAL DEVICE:

Class: Bioactive dental substitute (Tricalcium silicate) Dose: not applicable Application : one single time

DEVELOPMENTAL PHASE: not applicable (medical device class III)


Condition Intervention
Tooth Injury
Device: Application of Biodentine™ (RD94), dentin substitute

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III

Resource links provided by NLM:


Further study details as provided by Ascopharm Groupe Novasco:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 3 month follow-up.


Secondary Outcome Measures:
  • Long term efficacy and safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.


Enrollment: 53
Study Start Date: January 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Direct pulp capping/carious exposure
symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
Device: Application of Biodentine™ (RD94), dentin substitute
Experimental: Direct pulp capping/dental trauma
• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
Device: Application of Biodentine™ (RD94), dentin substitute
Experimental: Repairing root canals/pulp chamber floor
  • Iatrogenic perforation of the pulpal floor, with or without LEO.
  • Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
  • Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.
Device: Application of Biodentine™ (RD94), dentin substitute
Experimental: Retrograde endodontic surgery - adults
  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option
Device: Application of Biodentine™ (RD94), dentin substitute
Experimental: Pulpotomy in primary molars - children (3 to 12 years )
  • Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
  • Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.
Device: Application of Biodentine™ (RD94), dentin substitute
Experimental: Apexification - children (7 to 18 years) + adults
  • Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
  • Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
  • Apical Root Resorption
Device: Application of Biodentine™ (RD94), dentin substitute

Detailed Description:

METHODOLOGY:

This multi-centre and open-label study comprises six groups corresponding to the six indications tested. No placebo or reference product is involved. No randomization is required as the indication will define the patient selection.

The six indications studied are:

  • Direct pulp capping following carious pulp exposure
  • Direct pulp capping following dental trauma injury to healthy pulp (partial pulpotomy)
  • Repairing perforated root canals and/or the pulp chamber floor
  • Retrograde endodontic surgery
  • Pulpotomy in primary molars
  • Apexification

Study start: October 2009

Inclusion period: 1/10/2009 to 30/06/2011

Study duration: 2 years

OBJECTIVES:

The trial objective is to illustrate the clinical efficacy and tolerance of RD94 in the indications described.

Primary objective:

The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 6 month follow-up.

Secondary objective:

The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.

TRIAL POPULATION AND NUMBER OF PATIENTS:

60 patients in three French study centers, 10 per indication studied. Depending on the indication, children (from 3 years onwards), and/or adults will be included.

DURATION OF TREATMENT:

The product is applied on D0 (Inclusion) of the study. The follow-up period includes 2 years with six visits: Visit1 - Week 1, Visit 2 - Month 1, Visit 3 - Month 3, Visit 4 - Month 6, Visit 5 - Year 1, Visit 6 - Year 2.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • provide signed, informed consent.
  • be affiliated to social security. criteria for the corresponding indication: Direct pulp capping following carious pulp exposure - children (6 to 18 years) + adults
  • Symptomatic or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.

Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy - children (6 to 18 years) + adults

- Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.

Repairing perforated root canals and/or the pulp chamber floor - adults

  • Iatrogenic perforation of the pulpal floor, with or without LEO.
  • Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
  • Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.

Retrograde endodontic surgery - adults

  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option.

Pulpotomy in primary molars - children ( 3 to 12 years )

  • Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
  • Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.

Apexification - children (7 to 18 years) + adults

  • Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
  • Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
  • Apical Root Resorption

Exclusion Criteria

  1. History of malignancy in the last 5 years.
  2. Systemic disease not stabilized within 1 month before the Inclusion Visit or judged by the investigator to be incompatible with the study or condition incompatible with the frequent assessments needed by the study.

3 Risk A cardiopathies 4. Known hypersensitivity to one of the components of the study or procedural medications.

5. Presence or history of severe systemic allergy. 6. Presence or history of drug addiction or alcohol abuse. 7. Patient who has participated in a clinical trial with a new active substance during the month before study entry.

8. Participation in another clinical study at the same time as the present study.

9. Known pregnancy or lactation at study entry.

exclusion criteria for each indication : Direct pulp capping following carious pulp exposure

  • Chronic irreversible pulpitis
  • Pulp necrosis
  • Anterior or saliva-contaminated tooth pulp exposure
  • Accidental exposure occurring during non-retentive prosthetic preparation Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy
  • Pulp exposure period > 72 hours
  • Crown-root fracture
  • Pulpal necrosis with or without periapical disease(LEO)

Repairing perforated root canals and/or the pulp chamber floor

  • Supracrestal iatrogenic perforation
  • Inadequate periodontal support
  • Loss of tooth structure (Coronal decay and/or concomitant root decay) compromising the tooth's maintenance on the dental arch) Retrograde endodontic surgery
  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, when a working coronal restoration is either missing or presents microleakage
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when surgical treatment does not offer a more favorable risk-benefit ratio than the orthograde retreatment option
  • Insufficient periodontal support, endo-periodontal lesion
  • Coronal decay and/or concomitant root decay compromising the tooth's maintenance on the dental arch
  • Maxillary intrabony lesion of suspected non-endodontic origin

Pulpotomy:

  • Temporary molar expected to begin exfoliation within 24 months.
  • Molar presenting signs of irreversible pulp disease - spontaneous pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01737229

Locations
France
Service d'endodontie de la Pitié Salpêtrière Hôpital de la Pitié Salpêtrière
Paris, France
Cabinet de Chirurgie Dentaire rue Saint Didier
Paris, France
Service d'Odontologie Hôpital Rothschild
Paris, France
Sponsors and Collaborators
Ascopharm Groupe Novasco
AscoPharm is conducting the study under the responsibility of SEPTODONT
Investigators
Principal Investigator: Frédéric RILLIARD, Pr Université Paris 7-Denis Diderot
Principal Investigator: Chantal Naulin-Ifi, Docteur Service d'Odontologie du GHPS
Principal Investigator: Pierre Colon, Pr Université Paris VII Garancière.
  More Information

No publications provided

Responsible Party: Ascopharm Groupe Novasco
ClinicalTrials.gov Identifier: NCT01737229     History of Changes
Other Study ID Numbers: 09/001
Study First Received: November 6, 2012
Last Updated: July 23, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Tooth Injuries
Wounds and Injuries
Tooth Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on July 22, 2014